<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Microbes Infect</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Microbes Infect</journal-id><journal-title-group><journal-title>Emerging Microbes &#x00026; Infections</journal-title></journal-title-group><issn pub-type="epub">2222-1751</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">38922326</article-id><article-id pub-id-type="pmc">PMC467099</article-id>
<article-id pub-id-type="publisher-id">2373314</article-id><article-id pub-id-type="doi">10.1080/22221751.2024.2373314</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="heading"><subject>Emerging seasonal and pandemic influenza infections</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>R229I substitution from oseltamivir induction in HA1 region significantly increased the fitness of a H7N9 virus bearing NA 292K</article-title><alt-title alt-title-type="right-running-head">EMERGING MICROBES &#x00026; INFECTIONS</alt-title><alt-title alt-title-type="left-running-head">J. TANG ET AL.</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Jing</given-names></name><xref rid="AF1" ref-type="aff"/><xref rid="cor2" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Zou</surname><given-names>Shu-Mei</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Jian-Fang</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Rong-Bao</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Xin</surname><given-names>Li</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Xiao-Xu</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wei-Juan</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xi-Yan</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Yan-Hui</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Li-Qi</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Ning</given-names></name><xref rid="AF1" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4990-1016</contrib-id><name><surname>Wang</surname><given-names>Da-Yan</given-names></name><xref rid="AF1" ref-type="aff"/><xref rid="cor1" ref-type="corresp"/></contrib><aff id="AF1"><institution>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention; WHO Collaborating Centre for Reference and Research on Influenza; Key Laboratory for Medical Virology and Viral Diseases, National Health Commission; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Disease</institution>, <city>Beijing</city>, <country>People&#x02019;s Republic of China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>CONTACT</label> Da-Yan Wang <email xlink:href="wangdayan@ivdc.chinacdc.cn">wangdayan@ivdc.chinacdc.cn</email> National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, People's Republic of China</corresp><corresp id="cor2">Jing Tang <email xlink:href="tangjing@ivdc.chinacdc.cn">tangjing@ivdc.chinacdc.cn</email></corresp><fn id="FN1"><p>Supplemental data for this article can be accessed online at <ext-link xlink:href="10.1080/22221751.2024.2373314" ext-link-type="doi">https://doi.org/10.1080/22221751.2024.2373314</ext-link></p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>26</day><month>6</month><year>2024</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>6</month><year>2024</year></pub-date><volume>13</volume><issue>1</issue><elocation-id seq="180">2373314</elocation-id><pub-history><event event-type="received"><date><day>13</day><month>3</month><year>2024</year></date></event><event event-type="revised"><date><day>10</day><month>6</month><year>2024</year></date></event><event event-type="accepted"><date><day>22</day><month>6</month><year>2024</year></date></event><event event-type="tagger"><event-desc>Nova techset</event-desc><date><day>3</day><month>7</month><year>2024</year></date></event><event event-type="build-issue-online"><event-desc>Converted to JATS 1.2 by Nova Techset</event-desc><date><day>3</day><month>7</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2024 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="TEMI_13_2373314.pdf"/><abstract><title>ABSTRACT</title><p>The proportion of human isolates with reduced neuraminidase inhibitors (NAIs) susceptibility in highly pathogenic avian influenza (HPAI) H7N9 virus was high. These drug-resistant strains showed good replication capacity without serious loss of fitness. In the presence of oseltamivir, R229I substitution were found in HA1 region of the HPAI H7N9 virus before NA R292K appeared. HPAI H7N9 or H7N9/PR8 recombinant viruses were developed to study whether HA R229I could increase the fitness of the H7N9 virus bearing NA 292K. Replication efficiency was assessed in MDCK or A549 cells. Neuraminidase enzyme activity and receptor-binding ability were analyzed. Pathogenicity in C57 mice was evaluated. Antigenicity analysis was conducted through a two-way HI test, in which the antiserum was obtained from immunized ferrets. Transcriptomic analysis of MDCK infected with HPAI H7N9 24hpi was done. It turned out that HA R229I substitution from oseltamivir induction in HA1 region increased (1) replication ability in MDCK(<italic toggle="yes">P</italic> &#x0003c; 0.05) and A549(<italic toggle="yes">P</italic> &#x0003c; 0.05), (2) neuraminidase enzyme activity, (3) binding ability to both &#x003b1;2,3 and &#x003b1;2,6 receptor, (4) pathogenicity to mice(more weight loss; shorter mean survival day; viral titer in respiratory tract, <italic toggle="yes">P</italic> &#x0003c; 0.05; Pathological changes in pneumonia), (5) transcriptome response of MDCK, of the H7N9 virus bearing NA 292K. Besides, HA R229I substitution changed the antigenicity of H7N9/PR8 virus (&#x0003e;4-fold difference of HI titre). It indicated that through the fine-tuning of HA-NA balance, R229I increased the fitness and changed the antigenicity of H7N9 virus bearing NA 292K. Public health attention to this mechanism needs to be drawn.</p></abstract><abstract abstract-type="graphical"><title>GRAPHICAL ABSTRACT</title><fig position="anchor" id="UF0001"><alternatives><graphic xlink:href="TEMI_A_2373314_UF0001_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_UF0001_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>H7N9 influenza virus</kwd><kwd>HA1 R229I substitution</kwd><kwd>NA 292&#x02005;K</kwd><kwd>fitness</kwd><kwd>antigenic alteration</kwd></kwd-group><support-group><funding-group><award-group><funding-source><institution>National Natural Science Foundation of China Youth Fund</institution>
</funding-source><award-id>82102370</award-id></award-group><award-group><funding-source><institution>Young Scholar Science Foundation of China CDC</institution>
</funding-source><award-id>2022A103</award-id></award-group><award-group><funding-source><institution-wrap><institution>National Key R&#x00026;D Program of China</institution><institution-id institution-id-type="doi">10.13039/501100012166</institution-id></institution-wrap></funding-source><award-id>2023YFC2306003</award-id></award-group><funding-statement>This work was supported by National Natural Science Foundation of China (82102370), Young Scholar Science Foundation of China CDC (2022A103), National Key R&#x00026;D Program of China (2023YFC2306000).</funding-statement></funding-group></support-group><counts><fig-count count="9"/><table-count count="1"/><equation-count count="0"/><ref-count count="59"/><page-count count="15"/></counts></article-meta></front><body><sec sec-type="intro" disp-level="1" id="S001"><title>Introduction</title><p>In early 2013, the first human case of H7N9 avian influenza virus infection was reported globally [<xref rid="CIT0001" ref-type="bibr">1</xref>]. Since then, the H7N9 avian influenza virus has caused five wave epidemics of 1568 human laboratory-confirmed cases, including 616 deaths, with a case fatality rate of approximately 39% [<xref rid="CIT0002" ref-type="bibr">2</xref>]. The fifth wave of the H7N9 epidemic began in late 2016 and ended in the second half of 2017, with a total of 779 laboratory-confirmed cases, making it the most infected and geographically widespread wave of the H7N9 epidemic to date [<xref rid="CIT0003" ref-type="bibr">3</xref>]. Human infections with HPAI H7N9 virus were first detected in the fifth wave in China [<xref rid="CIT0003" ref-type="bibr">3</xref>]. As a mutant of the low pathogenic avian influenza(LPAI) H7N9 virus, poly-basic amino acids appeared at the HA cleavage site of the HPAI H7N9 virus [<xref rid="CIT0004" ref-type="bibr">4</xref>] to make it fatal to chickens. HPAI H7N9 has caused a total of 33 human laboratory-confirmed cases, including 16 deaths [<xref rid="CIT0005" ref-type="bibr">5</xref>]. At the end of 2016, the HPAI H7N9 virus broke out in poultry, which led to the use of the H5N1/H7N9 bivalent vaccine in Chinese poultry in September 2017. After vaccination, the infection rate of H7N9 in poultry significantly decreased, and the number of human cases of H7N9 avian influenza sharply decreased [<xref rid="CIT0006" ref-type="bibr">6</xref>]. Human infection with H7N9 avian influenza gradually came to an end in the second half of 2017. Sporadic cases of human infection with H7N9 virus were reported in 2018&#x0223c;2019 in China. Since March 2019, there have been no reported cases of human infection with H7N9 virus worldwide. However, the H7N9 virus has not been eradicated in poultry and other animals [<xref rid="CIT0007" ref-type="bibr">7&#x02013;9</xref>].</p><p>Antiviral drugs are an important measure of control for influenza in the population, particularly for those who are severely ill or hospitalized. Antivirals known as neuraminidase (NA) inhibitors and polymerase acidic (PA) inhibitors (PAI) have been approved in many countries for treating influenza cases clinically. The NAIs in current use are oral oseltamivir, inhaled zanamivir, intravenous peramivir, and inhaled laninamivir. In clinical, NA inhibitors were used to treat H7N9 virus-infected patients [<xref rid="CIT0010" ref-type="bibr">10</xref>]. Oseltamivir remains the most widely used influenza antiviral [<xref rid="CIT0011" ref-type="bibr">11</xref>]. However, the emergence of drug-resistant influenza strains can reduce antiviral efficacy.</p><p>In the previous studies, we examined the drug resistance profile of HPAI H7N9 isolates from Mainland of China (2016&#x02013;2019) and found 23% of them carried NAIs-resistance mutations, including NA R292K, E119V, etc. And 13% of them displayed reduced susceptibility to NAIs in the NA inhibition test [<xref rid="CIT0012" ref-type="bibr">12</xref>]. The proportion of strains carrying mutations related to reduced NAIs susceptibility in HPAI H7N9 was much higher than that seen previously in LPAI H7N9 or seasonal influenza virus isolates [<xref rid="CIT0011" ref-type="bibr">11</xref>,<xref rid="CIT0013" ref-type="bibr">13&#x02013;15</xref>]. Usually, NAIs-resistance mutations result in a loss in influenza viral fitness [<xref rid="CIT0016" ref-type="bibr">16</xref>,<xref rid="CIT0017" ref-type="bibr">17</xref>]. However, HPAI H7N9 viruses with reduced susceptibility to NAIs, even bearing the multidrug-resistant site of NA 292&#x02005;K (N2 numbering), showed good replication capacity without serious loss of fitness [<xref rid="CIT0018" ref-type="bibr">18&#x02013;20</xref>]. It may be restored by additional compensatory changes in the viral genome of HPAI H7N9 resistance strains. In our previous research, a non-mutant HPAI H7N9 recombinant virus by reverse genetics after serial viral passages under oseltamivir or zanamivir selection pressure generated NAIs-resistant mutations similar to that of clinical isolates of HPAI H7N9, including oseltamivir induced NA R292K substitution. Before NA R292K substitution appeared, R229I (H3 numbering) substitution was found in the HA1 region of the HPAI H7N9 virus, and no amino acid mutations were found in the internal genes of the recombinant virus [<xref rid="CIT0012" ref-type="bibr">12</xref>]. It has been reported that the HA1 mutation can rescue the weak growth capacity of a seasonal influenza virus, thereby compensating for the replication defect caused by carrying NAIs-resistance mutations [<xref rid="CIT0021" ref-type="bibr">21</xref>]. However, HA R229I substitution interacts with NA drug-resistant sites of the H7N9 virus have never been reported before. This research aimed at whether the single amino acid of R229I substitution from oseltamivir induction in the HA1 region could affect the fitness of an H7N9 virus bearing NA 292&#x02005;K in MDCK cells and C57 mice.</p><p>Haemagglutinin (HA) is the receptor-binding and membrane fusion glycoprotein of influenza viruses. It recognized sialic acid-containing, cell-surface glycoconjugates as receptors. Influenza viruses need to use sialic acid receptors to invade host cells, and the &#x003b1;-2,3 and &#x003b1;-2,6 sialic acids glycosidic bonds linking the terminal sialic acids are generally considered to be the most important factors influencing the cross-species transmission of the influenza viruses[<xref rid="CIT0022" ref-type="bibr">22</xref>]. The influenza virus receptors binding site is located at the distal membrane end of the HA molecule in a shallow, concave pocket consisting of a series of conserved amino acids at the base, including Y98, W153, H183, and Y195, flanked by secondary structural elements, including the 130-loop, 150-loop, 190-helix, and 220-loop [<xref rid="CIT0022" ref-type="bibr">22</xref>,<xref rid="CIT0023" ref-type="bibr">23</xref>]. Amino acid substitutions in the above-conserved region can influence both antibody binding and receptor binding [<xref rid="CIT0033" ref-type="bibr">33</xref>]. Key sites of amino acids, such as HA1 226/228 of H2/H3/H7 [<xref rid="CIT0024" ref-type="bibr">24</xref>,<xref rid="CIT0025" ref-type="bibr">25</xref>], HA1 190/225 of H1[<xref rid="CIT0026" ref-type="bibr">26</xref>,<xref rid="CIT0027" ref-type="bibr">27</xref>], HA1 196/226/228 of H5[<xref rid="CIT0028" ref-type="bibr">28</xref>] and 226 of H9[<xref rid="CIT0029" ref-type="bibr">29</xref>] subtype influenza virus, could affect the binding ability of influenza virus to receptors. HA1 229R, which was at the left edge of the receptor binding pocket, played an important role in maintaining its structural stability [<xref rid="CIT0030" ref-type="bibr">30</xref>] and conserved in influenza A virus [<xref rid="CIT0031" ref-type="bibr">31</xref>]. This study aimed to characterize the influence of HA R229I substitution on the binding ability of H7N9 virus receptors by direct receptor-binding analysis with synthetic sialylglycopolymers, and its impact on viral antigenicity by ferret experiment.</p></sec><sec sec-type="methods" disp-level="1" id="S002"><title>Materials and methods</title><sec disp-level="2" id="S002-S2001"><title>Generation of recombinant viruses</title><p>The HPAI H7N9 or H7N9/PR8 recombinant viruses were generated by reverse genetics. In short, the genes of HPAI H7N9 were from A/Guangdong/17SF006/2017 (abbreviated as 006) isolated from a human case. The (H7) N9 plasmid bearing 292R or 292&#x02005;K was developed before [<xref rid="CIT0018" ref-type="bibr">18</xref>]. HA gene after deletion of its highly pathogenic molecular markers (KRTA in 339&#x0223c;342 residues) was called HAdel [<xref rid="CIT0019" ref-type="bibr">19</xref>]. The internal six genes of the attenuated virus were from A/PR/8/34 (H1N1). The 006 strain encoded 229R in the HA protein. A single-point mutation was introduced to convert 229R to 229I in HA or HAdel.</p><p>R229I substitution was generated with the following primers:
<disp-quote specific-use="block"><p>HA or HAdel R229I Forward, gtattagccaatgaaagtcaattattccagattgaccattaacttgt,</p></disp-quote>
<disp-quote specific-use="block"><p>HA or HAdel R229I Reverse, acaagttaatggtcaatctggaataattgactttcattggctaatac.</p></disp-quote>The mutation was introduced into the HA or HAdel plasmid using the QuickChange Site-Directed Mutagenesis Kit (Stratagene). The eight plasmids were co-transfected into 293&#x02005;T/MDCK co-cultured monolayer for 72&#x02005;h. Supernatants in culture flask were inoculated in embryonated eggs at 37 &#x000b0;C. The hemagglutination test was used for the detection of positive viruses. Virus stocks were sequenced as described previously for verification, and virus titrations were determined with MDCK cells. The log<sub>10</sub>TCID<sub>50</sub>/mL was calculated by the Reed and Muench method. The recombinant H7N9/PR8 virus was evaluated as described before [<xref rid="CIT0019" ref-type="bibr">19</xref>].</p></sec><sec disp-level="2" id="S002-S2002"><title>Direct receptor-binding analysis with synthetic sialylglycopolymers</title><p>The receptor-binding ability of viruses was analyzed use of a soli dphase direct binding assay as described previously[<xref rid="CIT0032" ref-type="bibr">32</xref>], using two different synthetic sialylglycopolymers containing either &#x003b1;2,3-linked sialic acid (3&#x02032;-Sialyl-N-acetyllactosamine: Neu5Ac&#x003b1;2-3Gal&#x003b2;1-4GlcNAc&#x003b2;-sp3) (3&#x02032;SLN) or &#x003b1;2,6-linked sialic acid (6&#x02032;-Sialyl-N-acetyllactosamine: Neu5Ac&#x003b1;2-6Gal&#x003b2;1-4GlcNAc&#x003b2;-sp3) (6&#x02032;SLN) (GlycoNZ Corporation, USA). Briefly, clear microtitre plates (costar 3590) were incubated with serial two-fold dilutions of sialyglycopolymers. Following the plates were inoculated with 32 HA units of each virus. Then incubated with a human anti-H7 monoclonal antibody (MoAb) at 37 &#x000b0;C for 1&#x02005;h. The plates were incubated with the horseradish peroxidase (HRP)-conjugated goat-anti-Human IgG antibody (ZSGB-BIO, China) at 37 &#x000b0;C for 1&#x02005;h. Each sample was determined in duplicates and the optical density was determined at 450&#x02005;nm using the Epoch Microplate Spectrophotometer (Bio Tek, Beijing, China).</p></sec><sec disp-level="2" id="S002-S2003"><title>Growth kinetics in MDCK or A549 cells</title><p>The method of growth kinetics of H7N9 viruses in MDCK cells was described before [<xref rid="CIT0018" ref-type="bibr">18</xref>,<xref rid="CIT0019" ref-type="bibr">19</xref>]. Briefly speaking, MDCK cells were infected with the recombinant virus at an MOI of 0.001 at 37&#x000b0;C 5% CO2. Cells were washed twice with PBS after 1&#x02005;h of incubation, and an infection medium containing TPCK-trypsin was added. At time points 0, 18, 24, 48 and 72&#x02005;h post-infection (hpi), supernatants were collected, and 3 biological repeats were set up for each sample. Viral titres were determined on MDCK cells. The method of growth kinetics of H7N9 viruses in A549 cells was basically the same as the above method, except that the MOI is set to 0.1.</p></sec><sec disp-level="2" id="S002-S2004"><title>NA activity assays</title><p>NA enzyme activity was assessed in the fluorescence-based NA assay, using the NA-Fluor Influenza Neuraminidase Assay kit (Applied Biosystems, ThermoFisher) as previously described [<xref rid="CIT0033" ref-type="bibr">33</xref>] with minor modifications. Briefly, MDCK cells were infected with the recombinant viruses at an MOI of 0.001 at 37&#x000b0;C 5% CO<sub>2</sub>. The embryonated eggs were inoculated by the quantified recombinant viruses at 37&#x000b0;C. After 72&#x02005;h, the 2-fold dilutions of the collected cell supernatant or embryo allantoic fluid were determined for NA activities. NA activities were then expressed as a percentage of the counterpart viral total NA activity. Three replicates were set for each sample.</p></sec><sec disp-level="2" id="S002-S2005"><title>Pathogenicity in mice</title><p>The mouse experiment was conducted after the approval of the Ethics Committee of the National Institute for Viral Disease Control and Prevention, China CDC (20220207007). Specific-pathogen-free (SPF), female 8-week-old C57BL/6J mice were intranasal inoculated with 50&#x003bc;l of 10<sup>3</sup>&#x0223c;10<sup>6</sup> TCID<sub>50</sub> recombinant H7N9/PR8 virus under isoflurane anaesthesia. The weight change from 1 to 14 days post-infection (dpi) was calculated as a percentage of weight on 0&#x02005;dpi (n&#x02009;=&#x02009;5/group). Mice that showed severe disease and lost&#x02009;&#x02265;&#x02009;30% of initial weight were euthanized. On 1, 3 and 5&#x02005;dpi after inoculation, the lungs and trachea were removed from 5 mice of each group infected with 10<sup>4</sup>&#x0223c;10<sup>5</sup> TCID<sub>50</sub> virus, rinsed with sterile phosphate-buffered saline (PBS), homogenized, and resuspended in 1&#x02005;mL of PBS. The suspensions were cleared by centrifugation at 3000&#x000d7;g for 20&#x02005;min, and virus yield was determined by TCID<sub>50</sub> in MDCK cells. On 1, 3 and 5&#x02005;dpi, Lungs of mice infected with 10<sup>4</sup>&#x0223c;10<sup>5</sup> TCID<sub>50</sub> virus (<italic toggle="yes">n</italic>&#x02009;=&#x02009;5/group), were fixed in 10% paraformaldehyde and then for pathological study.</p></sec><sec disp-level="2" id="S002-S2006"><title>Lung histopathology and immunohistochemistry</title><p>The lung tissue of mice fixed with formalin was cut into sections and then stained with haematoxylin and eosin (H&#x00026;E). The distribution of antigens (influenza A nucleoprotein) was studied by immunohistochemistry (IHC). The primary antibody of anti-influenza A virus antibody(Abcam, ab20841) was diluted at a ratio of 1:200 before use in this study.</p></sec><sec disp-level="2" id="S002-S2007"><title>Ferret experiment</title><p>The ferret experiment was conducted after the approval of the Ethics Committee of the National Institute for Viral Disease Control and Prevention, China CDC (20220207008). Six-month-old adult male Andrew ferrets (Wuxi Sangosho Biotechnology Co., Ltd, China) weighing 2000g were infected with a virus by nasal drip after anaesthesia. Before immunization, ferrets were tested for influenza virus antibody, and ferrets without antibodies to influenza A (H1N1, H3N2, H7N9) and influenza B virus were selected as immune subjects. Ferret serum samples were collected 14 days after infection and after treatment with FR-50 receptor destroying enzyme (DENKA) were tested by two-way hemagglutination inhibition assay. A 4-fold higher difference in antibody titre between the reference and test antigen is interpreted as with antigenic difference.</p></sec><sec disp-level="2" id="S002-S2008"><title>Crystal structure display of the substitution in the HA and NA protein</title><p>The crystal structure of HA from the A/Guangdong/17SF003/2016 (hereafter called 003 for short) HPAI H7N9 virus (PDB ID: 6D7U) from the Protein Data Bank (PDB) was used as the backbone to display and label the HA substitution of NA R229I using DeepView v4.1.0 software. The HA crystal structure of 003 was selected for our analysis because both 003 and 006 strains are HPAI H7N9 viruses and their HA proteins are highly homologous. The crystal structure model of the NA monomer of A/ Anhui1/2013/H7N9 virus (PDB ID: 4MWJ) was used to display NA R292K using Raswin software.</p></sec><sec disp-level="2" id="S002-S2009"><title>Statistical analysis</title><p>Viral replication was analyzed by the GraphPad Prism 5.0 software. Two two-tailed unpaired Student&#x02019;s t test was used to evaluate differences between the two groups. A <italic toggle="yes">P</italic> value of &#x0003c;0.05 was considered significant.</p></sec><sec disp-level="2" id="S002-S2010"><title>Transcriptomic differential gene analysis of MDCK cells infected with HPAI H7N9 virus</title><p>MDCK cells were infected with the four recombinant HPAI H7N9 viruses at a MOI of 0.001. The mock group used PBS. Three biological replicates were set for each condition. Cells were collected for RNA sequencing analysis for differentially expressed genes and response to host cells. RNA sequencing was done by Biomarker Technologies (<ext-link xlink:href="http://www.biomarker.com.cn" ext-link-type="uri">www.biomarker.com.cn</ext-link>), and BMKCloud (<ext-link xlink:href="http://www.biocloud.net" ext-link-type="uri">www.biocloud.net</ext-link>) was used for analysis. DESeq2_edgeR was used for differential gene analysis. Fold Change&#x02009;&#x02265;&#x02009;1.5 and <italic toggle="yes">P</italic> value&#x02009;&#x0003c;&#x02009;0.01 were set as differential gene screening criteria.</p></sec><sec disp-level="2" id="S002-S2011"><title>Biosafety</title><p>All experiments involving HPAI H7N9 viruses were operated by qualified person in BSL-3 Laboratory of National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention.</p></sec></sec><sec sec-type="results" disp-level="1" id="S003"><title>Results</title><p>The NAIs-sensitive HPAI H7N9 virus constructed by reverse genetics containing NA 292R was called rg006 and that bearing NA 292K was called rg006NA292K. HPAI H7N9 reassortment virus bearing HA R229I was called rg006HA229I. HPAI H7N9 bearing HA R229I and NA 292K was called rg006HA229I-NA292&#x02005;K. Considering biological safety, some of the experiments were done with H7N9/PR8 attenuated strains. The NAIs-sensitive H7N9/PR8 virus containing NA 292R was called rg006NA/PR8 and that bearing NA 292&#x02005;K was called rg006NA292&#x02005;K/PR8. H7N9/PR8 reassortment virus bearing HAdel R229I was called rg006HA229I/PR8. H7N9/PR8 bearing HAdel R229I and NA 292&#x02005;K was called rg006HA229I-NA292&#x02005;K/PR8. The 8 recombinant viruses used in this study were confirmed by sequencing and listed in Supplementary Table S1.</p><sec disp-level="2" id="S003-S2001"><title>HA R229I substitution increased the replication and neuraminidase enzyme activity level of rg006NA292&#x02005;K/PR8</title><p>To test the effect of the HA R229I substitution on the growth characteristics of the H7N9 virus bearing NA292&#x02005;K, we determined infectious titres in MDCK or A549 cells. MDCK or A549 cells were infected with rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8, rg006/PR8 or rg006HA229I/PR8 virus by 0.001 MOI or 0.1 MOI respectively. As seen in <xref rid="F0001" ref-type="fig">Figure 1</xref>(A), the yields of rg006HA229I-NA292&#x02005;K/PR8 were significantly higher than that of rg006NA292&#x02005;K/PR8 (*<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) and even the sensitive strain of rg006/PR8 (#<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) at 18, 24, 48, and 72 hpi. The yields of rg006HA229I/PR8 were significantly higher than that of rg006/PR8 (&#x00026;<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) at 18, 24 and 48hpi and rg006/PR8 was significantly higher than that of rg006NA292&#x02005;K/PR8 (&#x0223c;<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) at 18, 24, 48, and 72 hpi. As seen in <xref rid="F0001" ref-type="fig">Figure 1</xref>(B), in A549 cells, the yields of rg006HA229I-NA292&#x02005;K/PR8 were significantly higher than that of rg006NA292&#x02005;K/PR8 at 18, 24 and 48hpi (*<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) and rg006/PR8 was significantly higher than that of rg006NA292&#x02005;K/PR8 (&#x0223c;<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) at 18, 24 and 72 hpi. Rg006HA229I-NA292&#x02005;K/PR8 display similar replication level to that of rg006/PR8 or rg006HA229I/PR8(P&#x0ff1e;0.05) in A549 cells. It suggested that the single mutation of HA R229I from oseltamivir induction significantly enhanced the replication ability of the H7N9-resistant strain (NA 292K) in MDCK or A549 cells. When the influenza virus acquired the drug-resistance mutation site of NA292K, its enzyme activity was greatly reduced. In order to study whether HA R229I substitution could increase the enzyme activity of rg006NA292&#x02005;K/PR8, a fluorescence-based NA assay was done. MDCK cells or embryonated eggs were infected with the recombinant virus at an MOI of 0.001, and after 72&#x02005;h, the collected supernatant was determined for NA activities. As seen in <xref rid="F0001" ref-type="fig">Figure 1</xref>(B), the neuraminidase enzyme activity level of rg006HA229I-NA292&#x02005;K/PR8 was4.44 and 5.85 times higher than that of rg006NA292&#x02005;K/PR8 in MDCK cell and embryonated egg at 72&#x02005;h respectively, which suggested HA R229I substitution increased the neuraminidase enzyme activity level of rg006NA292&#x02005;K/PR8.
<fig position="float" id="F0001"><label>Figure 1.</label><caption><p>Replication kinetics and neuraminidase enzyme activity. (A)MDCK Cells and (B) A549 Cells were inoculated with the four recombinant viruses at 37&#x000b0;C, and culture supernatants were harvested at 0, 18, 24, 48 and 72&#x02005;h post-inoculation (hpi). Each data point represents the mean log<sub>10&#x02009;</sub>&#x000b1;&#x02009;SD TCID<sub>50</sub>/mL from two independent experiments. Rg006NA292&#x02005;K/PR8 vs rg006HA229I-NA292&#x02005;K/PR8:*<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05;rg006HA229I-NA292&#x02005;K/PR8 vs rg006/PR8:#<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05; rg006/PR8 vs rg006HA229I/PR8:&#x00026;<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05;rg006NA292&#x02005;K/PR8 vs rg006/PR8:&#x0223c;<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05. (C) Enzyme activity of rg006NA292&#x02005;K/PR8 and rg006HA229I-NA292&#x02005;K/PR8 was determined by fluorimetric assays using MUN as substrate. Results are expressed as a percentage of the rg006NA292&#x02005;K/PR8 value (expressed as 100%). Mean values standard deviation calculated from three parallel groups.</p></caption><alternatives><graphic xlink:href="TEMI_A_2373314_F0001_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0001_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></p></sec><sec disp-level="2" id="S003-S2002"><title>HA R229I enhanced the binding affinitys of H7N9/PR8 to both &#x003b1;2,3 and &#x003b1;2,6-linked sialic acids receptor</title><p>A single point substitution of R229I in HA protein could increase the replication ability and NA enzyme activity of rg006NA292&#x02005;K/PR8 on MDCK cells, and HA 229aa was at the left edge of the receptor binding pocket. It is studied here that whether HA R229I increasing the fitness of an H7N9 virus bearing NA 292&#x02005;K by the mechanism of increasing the receptor binding ability. As shown in <xref rid="F0002" ref-type="fig">Figure 2</xref>, rg006NA292&#x02005;K/PR8 virus bound to sialic acid &#x003b1;2,3 and &#x003b1;2,6 receptors to some extent, as expected. Rg006HA229I-NA292&#x02005;K/PR8 showed increased affinity to both &#x003b1;2,3 and&#x003b1;2,6 receptors compared with rg006NA292&#x02005;K/PR8 virus. This phenomenon may explain why the HA R229I substitution located in the key position of receptor binding region could increase the fitness of drug-resistant strains of the H7N9 virus to mammalian cells by increasing the binding capacity of viruses to &#x003b1;2,3 and &#x003b1;2,6 receptors.
<fig position="float" id="F0002"><label>Figure 2.</label><caption><p>The binding ability of rg006NA292&#x02005;K/PR8 and rg006HA229I-NA292&#x02005;K/PR8 to both &#x003b1;2,3 and &#x003b1;2,6 receptors. Each sample was tested in duplicate. Absorbance was read at 450&#x02005;nm. Binding profiles of tested viruses are presented with glycans of 0, 0.625, 1.25, 2.5, 5 and 10&#x003bc;g/mL. (A): &#x003b1;2,3-linked sialic acid (3&#x02032;SLN). (B): &#x003b1;2,6-linked sialic acid (6&#x02032;SLN).</p></caption><alternatives><graphic xlink:href="TEMI_A_2373314_F0002_OB" content-type="black-white" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0002_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></p></sec><sec disp-level="2" id="S003-S2003"><title>HA R229I increased the pathogenicity of rg006NA292&#x02005;K/PR8 virus to C57 mice</title><p>The body weight curve and survival condition of 8-week-old female C57 mice infected with 10<sup>3</sup>&#x0223c;10<sup>6</sup> TCID<sub>50</sub> rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8&#x0ff0c;rg006/PR8 or rg006HA229I/PR8 are shown in <xref rid="F0003" ref-type="fig">Figure 3</xref>. When infection at 10<sup>3</sup>&#x0223c;10<sup>4</sup> TCID<sub>50</sub>, all mice infected with these four strains survived, but mice infected with rg006HA229I-NA292&#x02005;K/PR8 suffered from more weight loss than of rg006NA292&#x02005;K/PR8(<xref rid="F0003" ref-type="fig">Figure 3</xref>(A, B)). When the infection dose reached 10<sup>5</sup>TCID<sub>50</sub>, rg006NA292&#x02005;K/PR8 could lead to significant weight loss, but no fatality. As to rg006HA229I-NA292&#x02005;K/PR8, which suffer from more weight loss, lead to one death in mice (<xref rid="F0003" ref-type="fig">Figure 3</xref>(C)). When infected with the dose of 10<sup>6</sup> TCID<sub>50</sub>, rg006NA292&#x02005;K/PR8 could lead to significant weight loss, but without fatality. However, rg006HA229I-NA292&#x02005;K/PR8, similar to rg006/PR8 or rg006HA229I/PR8 strain, lead to much more weight loss than that of rg006NA292&#x02005;K/PR8, and two deaths in mice. When infected with the dose of 10<sup>5</sup>&#x0223c;10<sup>6</sup> TCID<sub>50</sub>, compared with rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8 shortened the mean survival day of mice (<xref rid="T0001" ref-type="table">Table 1</xref>).
<fig position="float" id="F0003"><label>Figure 3.</label><caption><p>Body weight curve and survival condition of mice infected with rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8, rg006/PR8 and rg006HA229I/PR8. Body weight change and survival condition of C57BL/6 mice (n&#x02009;=&#x02009;5/group) inoculated intranasal with 10<sup>3</sup>&#x0223c;10<sup>6</sup> TCID<sub>50</sub> recombinant viruses. Control group: PBS. (A) 10<sup>3</sup> TCID<sub>50</sub>;(B) 10<sup>4</sup> TCID<sub>50</sub>; (C) 10<sup>5</sup> TCID<sub>50</sub>; (D) 10<sup>6</sup> TCID<sub>50</sub>.</p></caption><alternatives><graphic xlink:href="TEMI_A_2373314_F0003_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0003_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig>
<table-wrap position="float" id="T0001" orientation="landscape"><label>Table 1.</label><caption><p>Pathogenicity of rg006NA292&#x02005;K/PR8/rg006HA229I-NA292&#x02005;K/PR8/rg006/PR8 and rg006HA229I/PR8 in a C57 mouse model.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead valign="bottom"><tr><th align="left">&#x000a0;</th><th colspan="3" align="center">rg006NA292&#x02005;K/PR8</th><th colspan="3" align="center">rg006HA229I-NA292&#x02005;K/PR8</th><th colspan="3" align="center">rg006/PR8</th><th colspan="3" align="center">rg006HA229I/PR8</th></tr><tr><th rowspan="3" align="left">Virus dose (TCID<sub>50</sub>)</th><th align="left">No.of mice</th><th rowspan="3" align="left">Survival rate</th><th rowspan="3" align="center">Mean survival day</th><th align="left">No.of mice</th><th rowspan="3" align="left">Survival rate</th><th rowspan="3" align="center">Mean survival day</th><th align="left">No.of mice</th><th rowspan="3" align="left">Survival rate</th><th rowspan="3" align="center">Mean survival day</th><th align="left">No.of mice</th><th rowspan="3" align="left">Survival rate</th><th rowspan="3" align="center">Mean survival day</th></tr><tr><th align="left">survived/</th><th align="left">survived/</th><th align="left">survived/</th><th align="left">survived/</th></tr><tr><th align="left">total No.</th><th align="left">total No.</th><th align="left">total No.</th><th align="left">total No.</th></tr></thead><tbody><tr><td align="left">10 <sup>3</sup></td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td></tr><tr><td align="left">10 <sup>4</sup></td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td></tr><tr><td align="left">10 <sup>5</sup></td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">4</td><td align="char" char=".">80%</td><td align="char" char="&#x000b1;">12&#x02009;&#x000b1;&#x02009;4</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td></tr><tr><td align="left">10 <sup>6</sup></td><td align="char" char=".">5</td><td align="char" char=".">100%</td><td align="char" char="&#x000b1;">14&#x02009;&#x000b1;&#x02009;0</td><td align="char" char=".">3</td><td align="char" char=".">60%</td><td align="char" char="&#x000b1;">10&#x02009;&#x000b1;&#x02009;5</td><td align="char" char=".">3</td><td align="char" char=".">60%</td><td align="char" char="&#x000b1;">10&#x02009;&#x000b1;&#x02009;6</td><td align="char" char=".">3</td><td align="char" char=".">60%</td><td align="char" char="&#x000b1;">10&#x02009;&#x000b1;&#x02009;6</td></tr></tbody></table></table-wrap></p><p>The viral load of rg006NA292&#x02005;K/PR8&#x0ff0c;rg006HA229I-NA292&#x02005;K/PR8&#x0ff0c;rg006/PR8 or rg006HA229I/PR8 in the respiratory tract of mice were shown in <xref rid="F0004" ref-type="fig">Figure 4</xref>. T test was used to analyze the difference of viral load of the 2 strains in different tissues (lung and trachea) at different time points (1, 3, 5&#x02005;dpi). The result showed that compared to rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8 caused higher viral titre in the lung tissue 1&#x02005;dpi (*<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05) of both 10<sup>4</sup> TCID<sub>50</sub> (<xref rid="F0004" ref-type="fig">Figure 4</xref>(A)) and10<sup>5</sup> TCID<sub>50</sub> group (<xref rid="F0004" ref-type="fig">Figure 4</xref>(C)). As in the trachea tissue, rg006HA229I-NA292&#x02005;K/PR8 caused a higher viral titre than that of rg006NA292&#x02005;K/PR8 1&#x02005;dpi (*<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05) of the 10<sup>5</sup> TCID<sub>50</sub> group (<xref rid="F0004" ref-type="fig">Figure 4</xref>(D)). The viral load rg006HA229I-NA292&#x02005;K/PR8 was higher than the sensitive strain of rg006/PR8 1&#x02005;dpi (#<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) (<xref rid="F0004" ref-type="fig">Figure 4</xref>(A,C)) in lung. It is suggested that after a single substitution of HA R229I, the fitness of the H7N9 virus bearing NA 292&#x02005;K to mice was significantly enhanced. Besides, the viral load rg006HA229I/PR8 was higher than rg006/PR8 1 and 3&#x02005;dpi(10<sup>4</sup> TCID<sub>50</sub>) (&#x00026;<italic toggle="yes">P&#x02009;</italic>&#x0003c;&#x02009;0.05) (<xref rid="F0004" ref-type="fig">Figure 4</xref>(A,C)) in lung.
<fig position="float" id="F0004"><label>Figure 4.</label><caption><p>Replication of rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8, rg006/PR8 and rg006HA229I/PR8 in the respiratory tract of mice. C57BL/6 mice (n&#x02009;=&#x02009;5/group) were inoculated intranasal with 10<sup>4</sup>TCID<sub>50</sub>(A,B) or 10<sup>5</sup>TCID<sub>50</sub>(C,D) of the viruses. Mice were euthanized at 1, 3 and 5&#x02005;dpi. Viral titres in the lung or trachea were determined on MDCK cells. rg006NA292&#x02005;K/PR8 vs rg006HA229I-NA292&#x02005;K/PR8:*<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05;rg006HA229I-NA292&#x02005;K/PR8 vs rg006/PR8:#<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05; rg006/PR8 vs rg006HA229I/PR8:&#x00026;<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05;rg006NA292&#x02005;K/PR8 vs rg006/PR8:&#x0223c;<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></caption><alternatives><graphic xlink:href="TEMI_A_2373314_F0004_OB" content-type="black-white" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0004_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></p><p>Lungs of mice infected with 10<sup>4</sup> or 10<sup>5</sup> TCID<sub>50</sub> viruses on 1, 3&#x02005;dpi or 5&#x02005;dpi were studied for pathology. In <xref rid="F0005" ref-type="fig">Figure 5</xref>(A), the lung tissue of the PBS control group of mice showed a normal shape without obvious change. The lung tissues infected with rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8, rg006/PR8 and rg006HA229I/PR8 showed inflammatory cell infiltration, alveolar injury and other pathological changes. At 10<sup>4</sup> and 10<sup>5</sup> TCID<sub>50</sub>, the lung tissues infected with rg006HA229I-NA292&#x02005;K/PR8 virus exhibited much more inflammatory infiltration and extensive pneumonia than that of rg006NA292&#x02005;K/PR8 group on 3&#x02005;dpi or 5&#x02005;dpi, especially in the 10<sup>5</sup> TCID<sub>50</sub> infection dose group after 5 days of infection. The inflammatory infiltration of the lung tissues infected with rg006HA229I-NA292&#x02005;K/PR8 was comparable to that of rg006/PR8 or rg006HA229I/PR8. Immunohistochemistry results shown in <xref rid="F0005" ref-type="fig">Figure 5</xref>(B), there is no NP antigen distribution in the lung tissue of PBS control group mice. After 10<sup>4</sup> TCID<sub>50</sub> or10<sup>5</sup> TCID<sub>50</sub> doses of infection, the lung tissues infected with the 4 viruses were stained with NP antigens. On 3 and 5&#x02005;dpi, a larger number of NP antigens were found in lung tissues infected with rg006HA229I-NA292&#x02005;K/PR8 virus which were widely distributed, compared with rg006NA292&#x02005;K/PR8 group, whether infected with 10<sup>4</sup> TCID<sub>50</sub> dose or 10<sup>5</sup>TCID<sub>50</sub> dose.
<fig-group position="float" id="F0005"><label>Figure 5.</label><caption><p>Pathological changes of lung tissue in mice infected with rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8, rg006/PR8 and rg006HA229I/PR8 viruses. The lung tissues of mice infected with 10<sup>4</sup>&#x0223c;10<sup>5</sup> TCID<sub>50</sub> rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8, rg006/PR8 and rg006HA229I/PR8 viruses were stained by haematoxylin and eosin ((A) HE&#x02009;&#x000d7;&#x02009;100) and NP antigen ((B) IHC&#x02009;&#x000d7;&#x02009;100)1, 3 or 5 days after infection. Control group: PBS.</p></caption><fig position="anchor" id="F0005a"><alternatives><graphic xlink:href="TEMI_A_2373314_F0005a_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0005a_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig><fig position="anchor" id="F0005b"><alternatives><graphic xlink:href="TEMI_A_2373314_F0005b_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0005b_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></fig-group></p></sec><sec disp-level="2" id="S003-S2004"><title>HA R229I changed the antigenicity of rg006/PR8 using ferret antiserum</title><p>Two six-month-old adult male Andrew ferrets were infected with rg006/PR8 or rg006HA229I/PR8 virus respectively by nasal drip after anaesthesia, and antiserum was collected 14 days later. As seen in <xref rid="F0006" ref-type="fig">Figure 6</xref>, compared to the rg006/PR8 virus, the rg006HA229I/PR8 virus displayed 4-fold difference (640:160) of HI titre to rg006/PR8 antiserum of ferret from challenged. Furthermore, compared to the rg006/PR8 virus, the rg006HA229I/PR8 virus displayed 64-fold difference (2560:40) of HI titre to rg006HA229I/PR8 antiserum of ferret from challenged. HA R229I changes the antigenicity of rg006/PR8.
<fig position="float" id="F0006"><label>Figure 6.</label><caption><p>Two-way HI test of the H7 R229I substitution strain and its wild-type counterpart using antiserum of ferret. Crystal structure model of the HA monomer from the A/Guangdong/SF003/2016 (PDB ID: 6D7U) strain was used to display and label the HA 229 amino acid, 229R: transparent, dashed line ball; R229I: purple, solid line ball. Six-month-old adult male Andrew ferrets were infected with rg006/PR8 or rg006HA229I/PR8 virus respectively by nasal drip after anaesthesia, and antiserum was collected 14 days later.</p></caption><alternatives><graphic xlink:href="TEMI_A_2373314_F0006_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0006_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></p></sec><sec disp-level="2" id="S003-S2005"><title>HA R229I conferred the HPAI H7N9 NA 292&#x02005;K strain much more influence to the host cells</title><p>To investigate the true impact of R229I mutation on the HPAI H7N9 virus, we infected MDCK cells with the four HPAI H7N9 recombinant viruses of rg006, rg006NA292&#x02005;K, rg006HA229I or rg006HA229I-NA292&#x02005;K and analyzed the host cell transcriptome level 24 hpi. As seen in <xref rid="F0007" ref-type="fig">Figure 7</xref>(A), rg006NA292&#x02005;K induced the host cells to produce a small number of DEGs (236, 122 up-regulation,114 down-regulation), which suggests the virus has a minor effect on MDCK cell at a MOI of 0.001 24hpi. However, rg006HA229I-NA292&#x02005;K could induce a much larger number of DEGs(8190, 4376 up-regulation, 3823 down-regulation) under the same conditions, just because of a single substitution of HA R229I. HA R229I conferred the HPAI H7N9 NA 292&#x02005;K strain induce much more DEGs, and the number of its DEGs was comparable to or even a bit more than that of rg006(7112, 3750 up-regulation, 3362 down-regulation) and rg006HA229I(8188, 4307 up-regulation, 3881 down-regulation). Venn diagram of differentially expressed genes among the four HPAI H7N9 viruses were shown in <xref rid="F0007" ref-type="fig">Figure 7</xref>(B), it showed rg006HA229I-NA292&#x02005;K only shared 174(account for 2.12% DEGs of rg006HA229I-NA292&#x02005;K) same DEGs with rg006NA292&#x02005;K, while it shared 6412(78.29% DEGs of rg006HA229I-NA292&#x02005;K) and 7026(85.79% DEGs of rg006HA229I-NA292&#x02005;K) same DEGs with rg006 and rg006HA229I respectively. It is suggested that compared to rg006NA292&#x02005;K, the cellular response caused by rg006HA229I-NA292&#x02005;K is more similar to that of rg006 and rg006HA229I. The pathway types in KEGG Classification, as in <xref rid="F0007" ref-type="fig">Figure 7</xref>(C), showed that similar to rg006 and rg006HA229I, rg006HA229I-NA292&#x02005;K could significantly affect the gene function and metabolic pathways of host cells, cause strong transcriptional changes and affect cell metabolism pathways.
<fig position="float" id="F0007"><label>Figure 7.</label><caption><p>Transcriptome response of MDCK cells induced by HPAI H7N9 viruses of rg006, rg006NA292&#x02005;K, rg006HA229I or rg006HA229I-NA292&#x02005;K. MDCK cells were infected with the four recombinant HPAI H7N9 viruses at a MOI of 0.001. Three biological replicates were set for each condition. Cells were collected at 24 hpi for RNA sequencing analysis. DESeq2_edgeR was used for differential gene analysis. Fold Change&#x02009;&#x02265;&#x02009;1.5 and <italic toggle="yes">P</italic> value&#x02009;&#x0003c;&#x02009;0.01 were set as differential gene screening criteria. M: Mock group(PBS); R: rg006; K: rg006NA292&#x02005;K; K-229I: rg006HA229I-NA292&#x02005;K; R-229I: rg006HA229I.(A) The number of differentially expressed genes. (B) Venn diagram of differentially expressed genes. The overlapping regions represent the number of differentially expressed genes shared among relevant combinations in this region. (C) KEGG enrichment network diagram of differentially expressed genes. The colour of the edges represents different pathways, and the colour of gene nodes represents multiple differences. The larger the pathway node, the more genes are enriched in that pathway. Here are the 5 most enriched pathways and related genes.</p></caption><alternatives><graphic xlink:href="TEMI_A_2373314_F0007_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="TEMI_A_2373314_F0007_PC" content-type="color" specific-use="print-only" position="float"/></alternatives></fig></p></sec></sec><sec sec-type="discussion" disp-level="1" id="S004"><title>Discussion</title><p>Association between Influenza HA mutations and reduced susceptibility to NAIs occurred. Several HA mutations did emerge during the clinical use of NAIs or have been observed in clinical specimens [<xref rid="CIT0012" ref-type="bibr">12</xref>,<xref rid="CIT0034" ref-type="bibr">34</xref>]. D222G was a studied NAI treatment-emergent H1 mutation in the seasonal influenza virus [<xref rid="CIT0021" ref-type="bibr">21</xref>]. The HA1 D222G mutation of A(H1N1)pdm09 had significantly longer ICU stays and was found with considerable frequency in fatal and severe cases [<xref rid="CIT0035" ref-type="bibr">35</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref>].</p><p>The transcriptomic differential gene analysis of MDCK cells infected with the HPAI H7N9 virus was done in the BSL-3 laboratory. It is suggested that a single substitution of HA1 R229I made the HPAI H7N9 strain bearing NA292&#x02005;K significantly affect the gene function and metabolic pathways of host cells, comparable to that of its sensitive strain. Considering biological safety and limitations on experimental conditions, the other experiments were done with H7N9/PR8 attenuated strains (HAdel gene and NA gene from HPAI H7N9) instead of the HPAI H7N9 viruses. Although the use of H7N9/PR8 attenuated strains can basically meet the requirements of this study regarding the NAIs-induced HA1 mutation compensating for the fitness loss caused by carrying NAIs resistance mutations, it cannot reflect the true pathogenicity of HPAI H7N9 viruses to mammalian cells and mice. Rg006HA229I-NA292&#x02005;K/PR8 exhibited much better replication ability (in MDCK and A549 cells) and higher enzyme activity (in MDCK cells) than that of rg006NA292&#x02005;K/PR8 due to HA R229I substitution (<xref rid="F0001" ref-type="fig">Figure 1</xref>). It suggested that HA R229I substitution could powerfully enhance the fitness of the H7N9 virus bearing NA 292&#x02005;K resistance mutation in mammalian cells. Consistently, the enzyme activity of rg006HA229I-NA292&#x02005;K/PR8 in chicken embryos is also higher than that of rg006NA292&#x02005;K/PR8, endowing better fitness of the drug-resistant strain.</p><p>In our previous research, H7N9/PR8 attenuated strains were used in the C57 mice experiment, when the infection dose&#x02009;&#x02264;&#x02009;10<sup>2</sup> TCID<sub>50</sub>, the pathogenicity of the virus to mice is fairly low [<xref rid="CIT0019" ref-type="bibr">19</xref>], therefore in this research the infection dose was set for 10<sup>3</sup>&#x0223c;10<sup>6</sup> TCID<sub>50.</sub> Because of H7N9/PR8 attenuated strains, the euthanized cut-off value for mice was set at lost&#x02009;&#x02265;&#x02009;30% of initial weight. Compared with rg006NA292&#x02005;K/PR8, rg006HA229I-NA292&#x02005;K/PR8 caused much weight loss, shorter survival days and even death in C57 mice due to HA R229I substitution (<xref rid="F0003" ref-type="fig">Figure 3</xref>, <xref rid="T0001" ref-type="table">Table 1</xref>). Besides, rg006HA229I-NA292&#x02005;K/PR8 replicated better than that of rg006NA292&#x02005;K/PR8 in the respiratory tract of mice (<xref rid="F0004" ref-type="fig">Figure 4</xref>) and accordingly led to more serious inflammatory infiltration and extensive pneumonia (<xref rid="F0005" ref-type="fig">Figure 5</xref>). It suggested that HA R229I substitution could enhance the fitness of the H7N9 virus bearing NA 292&#x02005;K resistance mutation in mice.</p><p>There is a consensus opinion that H7N9 viruses displayed dual receptor-binding specificity, meaning they could bind to both human-type &#x003b1;2,6 sialic acid receptors and avian-type &#x003b1;2,3 sialic acid receptors [<xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0037" ref-type="bibr">37</xref>]. HA L226Q Mutation has been widely confirmed as one of the key factors in the cross-species transmission of avian influenza virus and has been reported increasing receptor-binding avidity of influenza H7N9 virus [<xref rid="CIT0038" ref-type="bibr">38</xref>]. Besides, L226Q mutation is also considered critical for the antigenic differences between LPAI H7N9 viruses and HPAI H7N9 viruses [<xref rid="CIT0039" ref-type="bibr">39</xref>]. HA E190D or G225E could Increase receptor binding affinity of H1N1 virus and be associated with mammalian adaptation [<xref rid="CIT0040" ref-type="bibr">40</xref>,<xref rid="CIT0041" ref-type="bibr">41</xref>]. But, that HA R229I substitution could enhance the binding ability of H7N9 virus to both &#x003b1;2,3 and &#x003b1;2,6 receptors, has never been reported before. In this study, rg006HA229I-NA292&#x02005;K/PR8 showed much better receptor-binding avidity to both &#x003b1;2,3 and &#x003b1;2,6 receptors, due to a single amino acid substitution of HA R229I. That HA R229I enhanced the binding ability of H7N9/PR8 to both &#x003b1;2,3 and &#x003b1;2,6 receptors, may be one of the reasons how HA1 substitution rescues the weak growth capacity of a NAIs resistance strain.</p><p>The envelope glycoproteins, HA and NA, mediate host cell attachment and release, respectively. HA has functionally defined immunodominant antigenic sites that primarily map to the globular domain of the glycoprotein and surround the receptor binding site (RBS) [<xref rid="CIT0042" ref-type="bibr">42</xref>]. The modulation of viral HA receptor binding avidity can also lead to antigenic change and escape from antibody neutralization [<xref rid="CIT0043" ref-type="bibr">43</xref>,<xref rid="CIT0044" ref-type="bibr">44</xref>]. New variant strains can arise when mutations accumulate on the antigenic sites of HA and allow it to escape recognition by existing neutralizing antibodies, a process known as antigenic drift. Haemagglutinin mutations caused by neuraminidase antibody pressure could cause significant HA antigenic drift in the H9N2 influenza virus [<xref rid="CIT0045" ref-type="bibr">45</xref>]. The hemagglutination inhibition (HI) assay is the most commonly used method to analyze the antigenicity variation of influenza viruses [<xref rid="CIT0046" ref-type="bibr">46</xref>]. Since a 4-fold HI difference is considered a significant antigenic change [<xref rid="CIT0047" ref-type="bibr">47</xref>], the NAIs-induced HA R229I changed the antigenicity of the H7N9 virus in our study. The potential exists that NAIs selective pressure can contribute to the HA antigenic evolution. Besides, the H7N9 virus (rg006/PR8) exhibited poor HI reactivity to both itself(HI:160) and its mutant(HI:40) antiserum (<xref rid="F0006" ref-type="fig">Figure 6</xref>), which was consistent with the previous research [<xref rid="CIT0048" ref-type="bibr">48</xref>,<xref rid="CIT0049" ref-type="bibr">49</xref>]. However, after a single substitution occurred, rg006HA229I/PR8 exhibited better HI reactivity to both itself (HI:2560) and rg006/PR8(HI:640) antiserum.</p><p>HA and NA recognize the same molecule (sialic acid) with conflicting activities, it can be assumed that drastic changes in either activity would affect viral replication [<xref rid="CIT0050" ref-type="bibr">50</xref>]. The functional balance of two major transmembrane glycoproteins (HA and NA) was critical for virus fitness, which is reflected by the equilibrium between HA receptor binding and NA enzymatic activity. Balanced HA-NA functions are necessary for efficient influenza virus replication [<xref rid="CIT0050" ref-type="bibr">50&#x02013;52</xref>]. It suggested that high receptor affinity was associated with strong NA enzymatic activity, and low HA affinity was associated with weak NA enzymatic activity [<xref rid="CIT0053" ref-type="bibr">53</xref>]. There should be enough HA activity to ensure virus binding and enough NA activity to ensure the release of progeny virus [<xref rid="CIT0050" ref-type="bibr">50</xref>]. The fine-tuning of the HA&#x02013;NA receptor balance rather than the binding avidity of the influenza virus is the key element [<xref rid="CIT0054" ref-type="bibr">54</xref>]. In this study, a single substitution of R229I in the HA1 region increased the virus binding and NA activity of a H7N9 virus bearing NA 292&#x02005;K, so as to increase viral fitness in mammalian cells and mice. It demonstrated that R229I in HA1 made a better balance between HA and NA, so as to exhibit better HA-NA functions. A functional balance of activity between the two glycoproteins, resulting in an optimum level of HA affinity and NA enzymatic cleavage to allow for productive infection [<xref rid="CIT0055" ref-type="bibr">55</xref>]. The HA R229I substitution, easily observed from the oseltamivir induction experiment, have not been observed or reported in the HPAI H7N9 human cases. It is speculated that not just the specific HA1 R229I substitution could increase the fitness of H7N9 resistant strains, but a dynamic equilibrium of HA-NA improved viral fitness. The combination of HA1 R229I substitution and NA R292&#x02005;K of H7N9 virus is one of HA-NA balance, and there are still many combinations to be explored in the real world of the cases. Based on this, further exploration of deeper mechanisms is needed in the future.</p><p>As a single-stranded, negative-sense RNA virus, influenza virus has strong fitness, including compensatory ability against antiviral drugs. After decades, the use of M2 ion channel inhibitors, most currently circulating influenza strains are resistant to this once effective anti-influenza drug, and, therefore, the use of these inhibitors is not currently recommended [<xref rid="CIT0056" ref-type="bibr">56&#x02013;58</xref>]. Influenza viruses also developed antiviral resistance to NAIs or Baloxavir and evolved some potential compensatory substitutions for the disadvantages of drug-resistant strains [<xref rid="CIT0036" ref-type="bibr">36</xref>,<xref rid="CIT0059" ref-type="bibr">59</xref>]. Targeting the cunning influenza virus, it is important to strengthen basic research and surveillance to monitor the dynamic evolution of influenza viruses, so as to provide scientific information for drug development and clinical medication.</p><p>Influenza is a global challenge, and future pandemics of influenza are inevitable [<xref rid="CIT0037" ref-type="bibr">37</xref>]. The H7N9 epidemics taught us that influenza can emerge through reassortment and have a huge impact on human health. It is essential that closely monitor the key evolutionary changes of influenza viruses, especially zoonotic influenza viruses with pandemic potential, and be prepared for it.</p></sec><sec sec-type="conclusions" disp-level="1" id="S005"><title>Conclusions</title><p>R229I substitution from oseltamivir induction in HA1 region increased the replication ability in MDCK/A549 cells, transcriptome response of MDCK cells, neuraminidase enzyme activity, binding ability to &#x003b1;2,3/&#x003b1;2,6 receptor, and pathogenicity to C57 mice, of the H7N9 virus bearing NA 292&#x02005;K. Through the fine-tuning of the HA&#x02013;NA balance, this single point amino acid mutation located at the edge of the receptor binding pocket partially compensates for the fitness loss of the drug-resistant H7N9 influenza virus. Besides, R229I substitution from oseltamivir induction changed the antigenicity of the H7N9 virus, which suggests that NAIs selective pressure can contribute to the HA antigenic evolution of influenza viruses.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SM1159" position="float" content-type="local-data"><caption><title>Supplemental Material</title></caption><media xlink:href="TEMI_A_2373314_SM1159.docx"/></supplementary-material></sec></body><back><sec disp-level="1" id="S006"><title>Declarations</title></sec><sec sec-type="COI-statement" disp-level="1" id="S007"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><sec disp-level="1" id="S008"><title>Author contributions</title><p>Da-Yan Wang and Jing Tang designed the research. Jing Tang drafted the manuscript. Jing Tang, Shu-Mei Zou, Xiao-Xu Zeng, Wei-Juan Huang, Xi-Yan Li, Yan-Hui Cheng and Ning Xiao performed the experiment. Jing Tang, Shu-Mei Zou, Jian-Fang Zhou, Rong-Bao Gao provided methodology. Jing Tang and Shu-Mei Zou analyzed the data. Jing Tang, Li Xin, Wei-Juan Huang and Li-Qi Liu participated in discussions. Da-Yan Wang provided management and revised the manuscript. All authors read and approved the final manuscript.</p></sec><sec disp-level="1" id="S009"><title>Ethics approval and consent to participate</title><p>All animal experiments were conducted after the approval of the Ethics Committee of the National Institute for Viral Disease Control and Prevention, China CDC (20220207007, 20220207008).</p></sec><sec disp-level="1" id="S010"><title>Consent for publication</title><p>All the authors have agreed with the publication of this paper.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gao</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Cao</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Human infection with a novel avian-origin influenza A (H7N9) virus</article-title>. <source>N Engl J Med</source>. <year>2013</year>;<volume>368</volume>(<issue>20</issue>):<fpage>1888</fpage>&#x02013;<lpage>1897</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1304459</pub-id>. PubMed PMID: 23577628.<pub-id pub-id-type="pmid">23577628</pub-id>
</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Philippon</surname>
<given-names>DAM</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Cowling</surname>
<given-names>BJ</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Avian influenza human infections at the human-animal interface</article-title>. <source>J Infect Dis</source>. <year>2020</year>;<volume>222</volume>(<issue>4</issue>):<fpage>528</fpage>&#x02013;<lpage>537</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiaa105</pub-id>. Epub 2020/03/12. PubMed PMID: 32157291.<pub-id pub-id-type="pmid">32157291</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>P</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013&#x02013;17: an epidemiological study of laboratory-confirmed case series</article-title>. <source>Lancet Infect Dis</source>. <year>2017</year>;<volume>17</volume>(<issue>8</issue>):<fpage>822</fpage>&#x02013;<lpage>832</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s1473-3099(17)30323-7</pub-id><pub-id pub-id-type="pmid">28583578</pub-id>
</mixed-citation></ref><ref id="CIT0004"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Biological characterisation of the emerged highly pathogenic avian influenza (HPAI) A(H7N9) viruses in humans, in mainland China, 2016 to 2017</article-title>. <source>Eurosurveillance</source>. <year>2017</year>;<volume>22</volume>(<issue>19</issue>):<fpage>1</fpage>&#x02013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.2807/1560-7917.es.2017.22.19.30533</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yu</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Xiang</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>W</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The re-emergence of highly pathogenic avian influenza H7N9 viruses in humans in mainland China, 2019</article-title>. <source>Euro Surveill</source>. <year>2019 May</year>;<volume>24</volume>(<issue>21</issue>):<fpage>1900273</fpage>. doi:<pub-id pub-id-type="doi">10.2807/1560-7917</pub-id><pub-id pub-id-type="pmid">31138362</pub-id>
</mixed-citation></ref><ref id="CIT0006"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Tian</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Shi</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Vaccination of poultry successfully eliminated human infection with H7N9 virus in China</article-title>. <source>Sci China Life Sci</source>. <year>2018</year>;<volume>61</volume>(<issue>12</issue>):<fpage>1465</fpage>&#x02013;<lpage>1473</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11427-018-9420-1</pub-id>. Epub 2018/11/11. PubMed PMID: 30414008.<pub-id pub-id-type="pmid">30414008</pub-id>
</mixed-citation></ref><ref id="CIT0007"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Characterization of two chicken origin highly pathogenic H7N9 viruses isolated in northern China</article-title>. <source>Vet Microbiol</source>. <year>2022</year>;<volume>268</volume>:<fpage>109394</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vetmic.2022.109394</pub-id>. Epub 2022/03/23. PubMed PMID: 35316713.<pub-id pub-id-type="pmid">35316713</pub-id>
</mixed-citation></ref><ref id="CIT0008"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>He</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Spatiotemporal associations and molecular evolution of highly pathogenic avian influenza A H7N9 virus in China from 2017 to 2021</article-title>. <source>Viruses</source>. <year>2021</year>;<volume>13</volume>(<issue>12</issue>):<fpage>2524</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v13122524</pub-id>. Epub 2021/12/29. PubMed PMID: 34960793; PubMed Central PMCID: PMCPMC8705967.<pub-id pub-id-type="pmid">34960793</pub-id>
</mixed-citation></ref><ref id="CIT0009"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yin</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Fen</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Characterization of an H7N9 influenza virus isolated from camels in Inner Mongolia, China</article-title>. <source>Microbiol Spectr</source>. <year>2023 Feb 21</year>;<volume>11</volume>(<issue>2</issue>):<fpage>e0179822</fpage>. doi:<pub-id pub-id-type="doi">10.1128/spectrum.01798-22</pub-id><pub-id pub-id-type="pmid">36809036</pub-id>
</mixed-citation></ref><ref id="CIT0010"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>H.</given-names></string-name></person-group>
<article-title>H7N9 influenza virus in China</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2021</year>;<volume>11</volume>(<issue>8</issue>):<fpage>1</fpage>&#x02013;<lpage>17</lpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a038349</pub-id>. Epub 2020/03/25. PubMed PMID: 32205415; PubMed Central PMCID:PMCPMC8327827.</mixed-citation></ref><ref id="CIT0011"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Govorkova</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Takashita</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Daniels</surname>
<given-names>RS</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2018-2020</article-title>. <source>Antiviral Res</source>. <year>2022</year>;<volume>200</volume>:<fpage>105281</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.antiviral.2022.105281</pub-id>. Epub 2022/03/17. PubMed PMID: 35292289; PubMed Central PMCID: PMCPMC9254721.<pub-id pub-id-type="pmid">35292289</pub-id>
</mixed-citation></ref><ref id="CIT0012"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>SX</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Profile and generation of reduced neuraminidase inhibitor susceptibility in highly pathogenic avian influenza H7N9 virus from human cases in Mainland of China, 2016-2019</article-title>. <source>Virology</source>. <year>2020</year>;<volume>549</volume>:<fpage>77</fpage>&#x02013;<lpage>84</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virol.2020.07.018</pub-id>. Epub 2020/08/28. PubMed PMID: 32853849.<pub-id pub-id-type="pmid">32853849</pub-id>
</mixed-citation></ref><ref id="CIT0013"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lackenby</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Besselaar</surname>
<given-names>TG</given-names></string-name>, <string-name><surname>Daniels</surname>
<given-names>RS</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017</article-title>. <source>Antiviral Res</source>. <year>2018</year>;<volume>157</volume>:<fpage>38</fpage>&#x02013;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.antiviral.2018.07.001</pub-id>. Epub 2018/07/10. PubMed PMID: 29981793; PubMed Central PMCID: PMCPMC6094047.<pub-id pub-id-type="pmid">29981793</pub-id>
</mixed-citation></ref><ref id="CIT0014"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>W</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Two outbreak sources of influenza A (H7N9) viruses have been established in China</article-title>. <source>J Virol</source>. <year>2016</year>;<volume>90</volume>(<issue>12</issue>):<fpage>5561</fpage>&#x02013;<lpage>5573</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.03173-15</pub-id>. PubMed PMID: 27030268; PubMed Central PMCID: PMCPMC4886776.<pub-id pub-id-type="pmid">27030268</pub-id>
</mixed-citation></ref><ref id="CIT0015"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Huang</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Cheng</surname>
<given-names>YH</given-names></string-name>, <string-name><surname>Tan</surname>
<given-names>MJ</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Epidemiological and virological surveillance of influenza viruses in China during 2020-2021</article-title>. <source>Infect Dis Poverty</source>. <year>2022</year>;<volume>11</volume>(<issue>1</issue>):<fpage>74</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40249-022-01002-x</pub-id>. Epub 2022/06/30. PubMed PMID: 35768826; PubMed Central PMCID: PMCPMC9244124.<pub-id pub-id-type="pmid">35768826</pub-id>
</mixed-citation></ref><ref id="CIT0016"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Burnham</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Baranovich</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Marathe</surname>
<given-names>BM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>5</issue>):<fpage>2718</fpage>&#x02013;<lpage>2730</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.02628-13</pub-id>. PubMed PMID: 24566185; PubMed Central PMCID: PMCPMC3993273.<pub-id pub-id-type="pmid">24566185</pub-id>
</mixed-citation></ref><ref id="CIT0017"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yen</surname>
<given-names>HL</given-names></string-name>, <string-name><surname>Herlocher</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Hoffmann</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2005</year>;<volume>49</volume>(<issue>10</issue>):<fpage>4075</fpage>&#x02013;<lpage>4084</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.49.10.4075-4084.2005</pub-id>. Epub 2005/09/29. PubMed PMID: 16189083; PubMed Central PMCID: PMCPMC1251536.<pub-id pub-id-type="pmid">16189083</pub-id>
</mixed-citation></ref><ref id="CIT0018"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Highly pathogenic avian influenza H7N9 viruses with reduced susceptibility to neuraminidase inhibitors showed comparable replication capacity to their sensitive counterparts</article-title>. <source>Virol J</source>. <year>2019</year>;<volume>16</volume>(<issue>1</issue>):<fpage>87</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12985-019-1194-9</pub-id>. Epub 2019/07/04. PubMed PMID: 31266524; PubMed Central PMCID: PMCPMC6604316.<pub-id pub-id-type="pmid">31266524</pub-id>
</mixed-citation></ref><ref id="CIT0019"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gao</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Liu</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Substitution of I222L-E119&#x02005;V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>16293</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-95771-4</pub-id>. Epub 2021/08/13. PubMed PMID: 34381119; PubMed Central PMCID: PMCPMC8358046.<pub-id pub-id-type="pmid">34381119</pub-id>
</mixed-citation></ref><ref id="CIT0020"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Imai</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Watanabe</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kiso</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets</article-title>. <source>Cell Host Microbe</source>. <year>2017</year>;<volume>22</volume>(<issue>5</issue>):<fpage>615</fpage>&#x02013;<lpage>26 e8</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chom.2017.09.008</pub-id>. PubMed PMID: 29056430; PubMed Central PMCID: PMCPMC5721358.<pub-id pub-id-type="pmid">29056430</pub-id>
</mixed-citation></ref><ref id="CIT0021"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ilyushina</surname>
<given-names>NA</given-names></string-name>, <string-name><surname>Komatsu</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Ince</surname>
<given-names>WL</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Influenza A virus hemagglutinin mutations associated with use of neuraminidase inhibitors correlate with decreased inhibition by anti-influenza antibodies</article-title>. <source>Virol J</source>. <year>2019</year>;<volume>16</volume>(<issue>1</issue>):<fpage>149</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12985-019-1258-x</pub-id>. Epub 2019/12/01. PubMed PMID: 31783761; PubMed Central PMCID: PMCPMC6884823.<pub-id pub-id-type="pmid">31783761</pub-id>
</mixed-citation></ref><ref id="CIT0022"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Pu</surname>
<given-names>J.</given-names></string-name></person-group>
<article-title>Influence of host sialic acid receptors structure on the host specificity of influenza viruses</article-title>. <source>Viruses</source>. <year>2022</year>;<volume>14</volume>(<issue>10</issue>):<fpage>2141</fpage>. doi: <pub-id pub-id-type="doi">10.3390/v14102141</pub-id>. Epub 2022/10/28. PubMed PMID: 36298694; PubMed Central PMCID: PMCPMC9608321.<pub-id pub-id-type="pmid">36298694</pub-id>
</mixed-citation></ref><ref id="CIT0023"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gamblin</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Vachieri</surname>
<given-names>SG</given-names></string-name>, <string-name><surname>Xiong</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Hemagglutinin structure and activities</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2021</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1</fpage>&#x02013;<lpage>19</lpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a038638</pub-id>. Epub 2020/06/10. PubMed PMID: 32513673; PubMed Central PMCID: PMCPMC8485738</mixed-citation></ref><ref id="CIT0024"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>R</given-names></string-name>, <string-name><surname>McBride</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Paulson</surname>
<given-names>JC</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic</article-title>. <source>J Virol</source>. <year>2010</year>;<volume>84</volume>(<issue>4</issue>):<fpage>1715</fpage>&#x02013;<lpage>1721</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.02162-09</pub-id>. Epub 2009/12/17. PubMed PMID: 20007271; PubMed Central PMCID: PMCPMC2812380.<pub-id pub-id-type="pmid">20007271</pub-id>
</mixed-citation></ref><ref id="CIT0025"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Connor R</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kawaoka</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>WebsterR</surname>
<given-names>G</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Receptor specificity in human, avian, and equine H2 and H3 influenza virus isolates</article-title>. <source>Virology</source>. <year>1994 Nov 15</year>;<volume>205</volume>(<issue>1</issue>):<fpage>17</fpage>&#x02013;<lpage>23</lpage>. doi:<pub-id pub-id-type="doi">10.1006/viro.1994.1615</pub-id><pub-id pub-id-type="pmid">7975212</pub-id>
</mixed-citation></ref><ref id="CIT0026"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stevens</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Blixt</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Glaser</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities</article-title>. <source>J Mol Biol</source>. <year>2006</year>;<volume>355</volume>(<issue>5</issue>):<fpage>1143</fpage>&#x02013;<lpage>1155</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jmb.2005.11.002</pub-id>. Epub 2005/12/14. PubMed PMID: 16343533.<pub-id pub-id-type="pmid">16343533</pub-id>
</mixed-citation></ref><ref id="CIT0027"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Glaser</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zamarin</surname>
<given-names>D</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity</article-title>. <source>J Virol</source>. <year>2005</year>;<volume>79</volume>(<issue>17</issue>):<fpage>11533</fpage>&#x02013;<lpage>6</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.79.17.11533-11536.2005</pub-id>. Epub 2005/08/17. PubMed PMID: 16103207; PubMed Central PMCID: PMCPMC1193621.<pub-id pub-id-type="pmid">16103207</pub-id>
</mixed-citation></ref><ref id="CIT0028"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Blixt</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Stevens</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>In vitro evolution of H5N1 avian influenza virus toward human-type receptor specificity</article-title>. <source>Virology</source>. <year>2012</year>;<volume>422</volume>(<issue>1</issue>):<fpage>105</fpage>&#x02013;<lpage>113</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virol.2011.10.006</pub-id>. Epub 2011/11/08. PubMed PMID: 22056389; PubMed Central PMCID: PMCPMC5480292.<pub-id pub-id-type="pmid">22056389</pub-id>
</mixed-citation></ref><ref id="CIT0029"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matrosovich</surname>
<given-names>MN</given-names></string-name>, <string-name><surname>Krauss</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Webster</surname>
<given-names>RG.</given-names></string-name></person-group>
<article-title>H9n2 influenza A viruses from poultry in Asia have human virus-like receptor specificity</article-title>. <source>Virology</source>. <year>2001</year>;<volume>281</volume>(<issue>2</issue>):<fpage>156</fpage>&#x02013;<lpage>162</lpage>. doi:<pub-id pub-id-type="doi">10.1006/viro.2000.0799</pub-id>. Epub 2001/03/30. PubMed PMID: 11277689.<pub-id pub-id-type="pmid">11277689</pub-id>
</mixed-citation></ref><ref id="CIT0030"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McKimm-Breschkin</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Blick</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Sahasrabudhe</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Generation and characterization of variants of NWS G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2enand4-guanidino-Neu5Ac2en</article-title>. <source>AntimicrobAgentsChemother</source>. <year>1996 Jan</year>;<volume>40</volume>(<issue>1</issue>):<fpage>40</fpage>&#x02013;<lpage>46</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.40.1.40</pub-id></mixed-citation></ref><ref id="CIT0031"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>LM</given-names></string-name>, <string-name><surname>Carney</surname>
<given-names>PJ</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Structures of receptor complexes of a North American H7N2 influenza hemagglutinin with a loop deletion in the receptor binding site</article-title>. <source>PLoS Pathog</source>. <year>2010</year>;<volume>6</volume>(<issue>9</issue>):<fpage>e1001081</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.ppat.1001081</pub-id>. Epub 2010/09/09. PubMed PMID: 20824086; PubMed Central PMCID: PMCPMC2932715.<pub-id pub-id-type="pmid">20824086</pub-id>
</mixed-citation></ref><ref id="CIT0032"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zou</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Molecular characterization of H3 subtype avian influenza viruses based on poultry-related environmental surveillance in China between 2014 and 2017</article-title>. <source>Virology</source>. <year>2020</year>;<volume>542</volume>:<fpage>8</fpage>&#x02013;<lpage>19</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.virol.2020.01.003</pub-id>. Epub 2020/01/21. PubMed PMID: 31957664.<pub-id pub-id-type="pmid">31957664</pub-id>
</mixed-citation></ref><ref id="CIT0033"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Okomo-Adhiambo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nguyen</surname>
<given-names>HT</given-names></string-name>, <string-name><surname>Abd Elal</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Drug susceptibility surveillance of influenza viruses circulating in the United States in 2011-2012: application of the WHO antiviral working group criteria</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2014</year>;<volume>8</volume>(<issue>2</issue>):<fpage>258</fpage>&#x02013;<lpage>265</lpage>. doi:<pub-id pub-id-type="doi">10.1111/irv.12215</pub-id>. PubMed PMID: 24299049; PubMed Central PMCID: PMCPMC4186475.<pub-id pub-id-type="pmid">24299049</pub-id>
</mixed-citation></ref><ref id="CIT0034"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yates</surname>
<given-names>PJ</given-names></string-name>, <string-name><surname>Raimonde</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Zhao</surname>
<given-names>HH</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects</article-title>. <source>Antiviral Res</source>. <year>2016</year>;<volume>134</volume>:<fpage>144</fpage>&#x02013;<lpage>152</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.antiviral.2016.08.023</pub-id>. Epub 2016/08/30. PubMed PMID: 27568923.<pub-id pub-id-type="pmid">27568923</pub-id>
</mixed-citation></ref><ref id="CIT0035"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname>
<given-names>PK</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Joynt</surname>
<given-names>GM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Clinical and virological course of infection with haemagglutinin D222G mutant strain of 2009 pandemic influenza A (H1N1) virus</article-title>. <source>J Clin Virol</source>. <year>2011</year>;<volume>50</volume>(<issue>4</issue>):<fpage>320</fpage>&#x02013;<lpage>324</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcv.2011.01.013</pub-id>. Epub 2011/02/19. PubMed PMID: 21330192.<pub-id pub-id-type="pmid">21330192</pub-id>
</mixed-citation></ref><ref id="CIT0036"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Melidou</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Gioula</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Exindari</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Genetic analysis of post-pandemic 2010-2011 influenza A(H1N1)pdm09 hemagglutinin virus variants that caused mild, severe, and fatal infections in Northern Greece</article-title>. <source>J Med Virol</source>. <year>2015</year>;<volume>87</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jmv.23990</pub-id>. Epub 2014/06/06. PubMed PMID: 24898533.<pub-id pub-id-type="pmid">24898533</pub-id>
</mixed-citation></ref><ref id="CIT0037"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>L</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The epidemiology, virology, and pathogenicity of human infections with avian influenza viruses</article-title>. <source>Cold Spring Harb Perspect Med</source>. <year>2021</year>;<volume>11</volume>(<issue>4</issue>):<fpage>1</fpage>&#x02013;<lpage>18</lpage>. doi: <pub-id pub-id-type="doi">10.1101/cshperspect.a038620</pub-id>. Epub 2020/01/23. PubMed PMID: 31964651; PubMed Central PMCID: PMCPMC8015695.</mixed-citation></ref><ref id="CIT0038"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Lv</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Niu</surname>
<given-names>X</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>L226q mutation on influenza H7N9 virus hemagglutinin increases receptor-binding avidity and leads to biased antigenicity evaluation</article-title>. <source>J Virol</source>. <year>2020</year>;<volume>94</volume>(<issue>20</issue>)<fpage>1</fpage>&#x02013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.00667-20</pub-id>. Epub 2020/08/17. PubMed PMID:32796071; PubMed Central PMCID: PMCPMC7527056.</mixed-citation></ref><ref id="CIT0039"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chang</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sealy</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Sadeyen</surname>
<given-names>JR</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Amino acid residue 217 in the hemagglutinin glycoprotein is a key mediator of avian influenza H7N9 virus antigenicity</article-title>. <source>J Virol</source>. <year>2019</year>;<volume>93</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1128/JVI.01627-18</pub-id>. Epub 2018/10/05. PubMed PMID: 30282714; PubMed Central PMCID: PMCPMC6288333.</mixed-citation></ref><ref id="CIT0040"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Griffin</surname>
<given-names>EF</given-names></string-name>, <string-name><surname>Tompkins</surname>
<given-names>SM.</given-names></string-name></person-group>
<article-title>Fitness determinants of influenza A viruses</article-title>. <source>Viruses</source>. <year>2023</year>;<volume>15</volume>(<issue>9</issue>)<fpage>1</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.3390/v15091959</pub-id>. Epub 2023/09/28. PubMed PMID: 37766365; PubMed Central PMCID: PMCPMC10535923.</mixed-citation></ref><ref id="CIT0041"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matrosovich</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tuzikov</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bovin</surname>
<given-names>N</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Early alterations of the receptor-binding properties of H1, H2, and H3 avian influenza virus hemagglutinins after their introduction into mammals</article-title>. <source>J Virol</source>. <year>2000 Sep</year>;<volume>74</volume>(<issue>18</issue>):<fpage>8502</fpage>&#x02013;<lpage>8512</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jvi.74.18.8502-8512.2000</pub-id><pub-id pub-id-type="pmid">10954551</pub-id>
</mixed-citation></ref><ref id="CIT0042"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Caton A</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Brownlee G</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Yewdell J</surname>
<given-names>W</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The antigenic structure of the influenza VirusAPR834Hemagglutinin(HISubtype)</article-title>. <source>Cell</source>. <year>1982 Dec</year>;<volume>31</volume>(<issue>2Pt1</issue>):<fpage>417</fpage>&#x02013;<lpage>427</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0092-8674(82)90135-0</pub-id><pub-id pub-id-type="pmid">6186384</pub-id>
</mixed-citation></ref><ref id="CIT0043"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koel</surname>
<given-names>BF</given-names></string-name>, <string-name><surname>Burke</surname>
<given-names>DF</given-names></string-name>, <string-name><surname>Bestebroer</surname>
<given-names>TM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution</article-title>. <source>Science</source>. <year>2013</year>;<volume>342</volume>(<issue>6161</issue>):<fpage>976</fpage>&#x02013;<lpage>979</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1244730</pub-id>. Epub 2013/11/23. PubMed PMID: 24264991.<pub-id pub-id-type="pmid">24264991</pub-id>
</mixed-citation></ref><ref id="CIT0044"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hensley</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Das</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Bailey</surname>
<given-names>AL</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift</article-title>. <source>Science</source>. <year>2009</year>;<volume>326</volume>(<issue>5953</issue>):<fpage>734</fpage>&#x02013;<lpage>736</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.1178258</pub-id>. Epub 2009/11/11. PubMed PMID: 19900932; PubMed Central PMCID: PMCPMC2784927.<pub-id pub-id-type="pmid">19900932</pub-id>
</mixed-citation></ref><ref id="CIT0045"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wang</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wan</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Identification of hemagglutinin mutations caused by neuraminidase antibody pressure</article-title>. <source>Microbiol Spectr</source>. <year>2021 Dec 22</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e0143921</fpage>. doi:<pub-id pub-id-type="doi">10.1128/spectrum.01439-21</pub-id>. Epub 2021 Dec 22.<pub-id pub-id-type="pmid">34937172</pub-id>
</mixed-citation></ref><ref id="CIT0046"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Bostick</surname>
<given-names>DL</given-names></string-name>, <string-name><surname>Sullivan</surname>
<given-names>CB</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Single hemagglutinin mutations that alter both antigenicity and receptor binding avidity influence influenza virus antigenic clustering</article-title>. <source>J Virol</source>. <year>2013</year>;<volume>87</volume>(<issue>17</issue>):<fpage>9904</fpage>&#x02013;<lpage>9910</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.01023-13</pub-id>. Epub 2013/07/05. PubMed PMID: 23824816; PubMed Central PMCID: PMCPMC3754131.<pub-id pub-id-type="pmid">23824816</pub-id>
</mixed-citation></ref><ref id="CIT0047"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Klingen</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Reimering</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guzman</surname>
<given-names>CA</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>In silico vaccine strain prediction for human influenza viruses</article-title>. <source>Trends Microbiol</source>. <year>2018</year>;<volume>26</volume>(<issue>2</issue>):<fpage>119</fpage>&#x02013;<lpage>131</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2017.09.001</pub-id>. Epub 2017/10/17. PubMed PMID: 29032900.<pub-id pub-id-type="pmid">29032900</pub-id>
</mixed-citation></ref><ref id="CIT0048"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>J</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>The effect of single amino acid substitution at position 220 in the hemagglutinin glycoprotein on avian influenza H7N9 candidate vaccine virus</article-title>. <source>Virus Genes</source>. <year>2021</year>;<volume>57</volume>(<issue>2</issue>):<fpage>164</fpage>&#x02013;<lpage>171</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11262-021-01827-y</pub-id>. Epub 2021/02/20. PubMed PMID: 33606171.<pub-id pub-id-type="pmid">33606171</pub-id>
</mixed-citation></ref><ref id="CIT0049"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>Z</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>220 mutation in the hemagglutinin of avian influenza A (H7N9) virus alters antigenicity during vaccine strain development</article-title>. <source>Hum Vaccin Immunother</source>. <year>2018</year>;<volume>14</volume>(<issue>3</issue>):<fpage>532</fpage>&#x02013;<lpage>539</lpage>. doi:<pub-id pub-id-type="doi">10.1080/21645515.2017.1419109</pub-id>. PubMed PMID: 29300686; PubMed Central PMCID: PMCPMC5861781.<pub-id pub-id-type="pmid">29300686</pub-id>
</mixed-citation></ref><ref id="CIT0050"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitnaul</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Matrosovich</surname>
<given-names>MN</given-names></string-name>, <string-name><surname>Castrucci</surname>
<given-names>MR</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus</article-title>. <source>J Virol</source>. <year>2000 Jul</year>;<volume>74</volume>(<issue>13</issue>):<fpage>6015</fpage>&#x02013;<lpage>6020</lpage>. doi:<pub-id pub-id-type="doi">10.1128/jvi.74.13.6015-6020.2000</pub-id><pub-id pub-id-type="pmid">10846083</pub-id>
</mixed-citation></ref><ref id="CIT0051"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wallace</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>de Vries</surname>
<given-names>E</given-names></string-name>, <string-name><surname>van Kuppeveld</surname>
<given-names>FJM</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Neuraminidase-dependent entry of influenza A virus is determined by hemagglutinin receptor-binding specificity</article-title>. <source>J Virol</source>. <year>2023 Oct 31</year>;<volume>97</volume>(<issue>10</issue>):<fpage>e0060223</fpage>. doi:<pub-id pub-id-type="doi">10.1128/jvi.00602-23</pub-id>. Epub 2023 Sep 27.<pub-id pub-id-type="pmid">37754760</pub-id>
</mixed-citation></ref><ref id="CIT0052"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lai</surname>
<given-names>JCC</given-names></string-name>, <string-name><surname>Karunarathna</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wong</surname>
<given-names>HH</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Neuraminidase activity and specificity of influenza A virus are influenced by haemagglutinin-receptor binding</article-title>. <source>Emerg Microbes Infect</source>. <year>2019</year>;<volume>8</volume>(<issue>1</issue>):<fpage>327</fpage>&#x02013;<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.1080/22221751.2019.1581034</pub-id>. Epub 2019/03/15. PubMed PMID: 30866786; PubMed Central PMCID: PMCPMC6455212.<pub-id pub-id-type="pmid">30866786</pub-id>
</mixed-citation></ref><ref id="CIT0053"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zhu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>McBride</surname>
<given-names>R</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Functional balance of the hemagglutinin and neuraminidase activities accompanies the emergence of the 2009 H1N1 influenza pandemic</article-title>. <source>J Virol</source>. <year>2012</year>;<volume>86</volume>(<issue>17</issue>):<fpage>9221</fpage>&#x02013;<lpage>9232</lpage>. doi:<pub-id pub-id-type="doi">10.1128/JVI.00697-12</pub-id>. Epub 2012/06/22. PubMed PMID: 22718832; PubMed Central PMCID: PMCPMC3416152.<pub-id pub-id-type="pmid">22718832</pub-id>
</mixed-citation></ref><ref id="CIT0054"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>de Vries</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Influenza A virus hemagglutinin-neuraminidase-receptor balance: preserving virus motility</article-title>. <source>Trends Microbiol</source>. <year>2020</year>;<volume>28</volume>(<issue>1</issue>):<fpage>57</fpage>&#x02013;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.tim.2019.08.010</pub-id>. Epub 2019/10/21. PubMed PMID: 31629602; PubMed Central PMCID: PMCPMC7172302.<pub-id pub-id-type="pmid">31629602</pub-id>
</mixed-citation></ref><ref id="CIT0055"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byrd-Leotis</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cummings</surname>
<given-names>RD</given-names></string-name>, <string-name><surname>Steinhauer</surname>
<given-names>DA.</given-names></string-name></person-group>
<article-title>The interplay between the host receptor and influenza virus hemagglutinin and neuraminidase</article-title>. <source>Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms18071541</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Zhou</surname>
<given-names>Y</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Discovery of highly potent pinanamine-based inhibitors against amantadine- and oseltamivir-resistant influenza A viruses</article-title>. <source>J Med Chem</source>. <year>2018</year>;<volume>61</volume>(<issue>12</issue>):<fpage>5187</fpage>&#x02013;<lpage>5198</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00042</pub-id>. Epub 2018/05/26. PubMed PMID: 29799746; PubMed Central PMCID: PMCPMC6496959.<pub-id pub-id-type="pmid">29799746</pub-id>
</mixed-citation></ref><ref id="CIT0057"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Perez</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Schafer</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Influenza virus: small molecule therapeutics and mechanisms of antiviral resistance</article-title>. <source>Curr Med Chem</source>. <year>2018</year>;<volume>25</volume>(<issue>38</issue>):<fpage>5115</fpage>&#x02013;<lpage>5127</lpage>. doi:<pub-id pub-id-type="doi">10.2174/0929867324666170920165926</pub-id>. Epub 2017/09/22. PubMed PMID: 28933281; PubMed Central PMCID: PMCPMC8735713.<pub-id pub-id-type="pmid">28933281</pub-id>
</mixed-citation></ref><ref id="CIT0058"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uyeki</surname>
<given-names>TM</given-names></string-name>, <string-name><surname>Hui</surname>
<given-names>DS</given-names></string-name>, <string-name><surname>Zambon</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Influenza</article-title>. <source>Lancet</source>. <year>2022</year>;<volume>400</volume>(<issue>10353</issue>):<fpage>693</fpage>&#x02013;<lpage>706</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0140-6736(22)00982-5</pub-id><pub-id pub-id-type="pmid">36030813</pub-id>
</mixed-citation></ref><ref id="CIT0059"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickerson</surname>
<given-names>BT</given-names></string-name>, <string-name><surname>Petrovskaya</surname>
<given-names>SN</given-names></string-name>, <string-name><surname>Dickensheets</surname>
<given-names>H</given-names></string-name>, <etal>et al.</etal></person-group>
<article-title>Impact of Baloxavir resistance-associated substitutions on influenza virus growth and drug susceptibility</article-title>. <source>J Virol</source>. <year>2023 Jul 27</year>;<volume>97</volume>(<issue>7</issue>):<fpage>e0015423</fpage>. doi:<pub-id pub-id-type="doi">10.1128/jvi.00154-23</pub-id>. Epub 2023 Jul 5.<pub-id pub-id-type="pmid">37404185</pub-id>
</mixed-citation></ref></ref-list></back></article>